Atrial Fibrilasi

01Pathophysiology

Normal sinus rhythm depends on a single, organized electrical impulse originating from the sinoatrial node, traveling through the atria in a coordinated fashion, and arriving at the atrioventricular (AV) node. In atrial fibrillation, this organized conduction is replaced by multiple chaotic, micro-re-entrant circuits firing simultaneously throughout the atrial myocardium. The atria depolarize in a completely disorganized manner at rates of 350 to 600 impulses per minute, producing the characteristic fibrillatory baseline on ECG rather than discrete P waves.

The AV node serves as a gatekeeper and cannot conduct all of these impulses to the ventricles. It allows a variable, unpredictable number of impulses through, which is why the ventricular response is irregularly irregular. This is the single most important rhythm characteristic and should immediately trigger consideration of atrial fibrillation on any exam vignette.

Because the atria are fibrillating rather than contracting in a coordinated way, the so-called "atrial kick" is lost. The atrial kick normally contributes approximately 15 to 25 percent of ventricular filling during late diastole. Its loss reduces cardiac output and explains the fatigue, dyspnea, and exercise intolerance that patients report. In patients who depend heavily on this contribution, such as those with heart failure with preserved ejection fraction (HFpEF) or mitral stenosis, the hemodynamic consequences are particularly severe.

The loss of effective atrial contraction also leads to blood stasis, predominantly in the left atrial appendage (LAA). Stagnant blood activates the coagulation cascade, forming thrombus. When this thrombus embolizes, it most commonly travels to the cerebral vasculature, producing an ischemic stroke. This is why anticoagulation is central to the management and why a stroke may be the very first presentation of previously undiagnosed atrial fibrillation.

Over time, atrial fibrillation itself begets further atrial fibrillation through a process of electrical and structural remodeling. Persistent high atrial rates shorten the atrial refractory period (electrical remodeling) and promote atrial fibrosis and dilation (structural remodeling), making the arrhythmia progressively harder to terminate. This is the concept behind the phrase "AF begets AF."

A chronically uncontrolled ventricular rate (persistent tachycardia above 100 to 110 bpm) can lead to tachycardia-induced cardiomyopathy, a reversible form of dilated cardiomyopathy that improves with adequate rate control. This is a testable concept: a vignette may present a patient with new-onset heart failure and a fast, irregular rhythm, and the correct answer is that controlling the rate can recover ventricular function.

02Classification and Clinical Manifestation

Classification

Clinical Manifestation by Mechanism

03Diagnostic Workup

The best initial test for any patient with a suspected arrhythmia is a 12-lead ECG. The hallmark findings are the triad of (1) irregularly irregular R-R intervals, (2) absence of organized P waves, and (3) a fibrillatory or undulating baseline. If all three are present, the diagnosis is confirmed. Narrow QRS complexes are expected because ventricular conduction is normal.

If the patient reports episodic palpitations but the ECG at the time of evaluation is in sinus rhythm, the arrhythmia must be captured with ambulatory monitoring. A Holter monitor (24 to 48 hours) is appropriate for frequent symptoms. For infrequent episodes, an event monitor or implantable loop recorder provides longer surveillance.

Every newly diagnosed patient should undergo a transthoracic echocardiogram to evaluate left atrial size (chronic dilation supports chronicity), left ventricular ejection fraction, and valvular pathology. Finding moderate-to-severe mitral stenosis or a mechanical valve reclassifies the patient as having valvular atrial fibrillation, which directly changes the anticoagulation strategy.

A TSH level must be checked in every new diagnosis of atrial fibrillation. Hyperthyroidism is one of the few truly reversible causes, and treating the thyroid disorder may resolve the arrhythmia entirely. This is a frequently tested concept: the question may describe a patient with weight loss, heat intolerance, tremor, and new-onset palpitations, and the answer is to check TSH.

Transesophageal echocardiography (TEE) is the most accurate test for identifying thrombus in the left atrial appendage. It is ordered when cardioversion is planned and the arrhythmia has lasted longer than 48 hours (or the duration is unknown). If TEE shows no thrombus, cardioversion can proceed. If thrombus is present, cardioversion must be deferred and the patient must be anticoagulated for at least 3 to 4 weeks before reattempting.

04Management and Treatment

Acute Stabilization

If the patient is hemodynamically unstable, the answer is always immediate synchronized cardioversion, regardless of anticoagulation status or duration of the arrhythmia. Do not waste time obtaining a TEE or starting heparin in an unstable patient. This is a "next best step" question that appears repeatedly.

If the patient is hemodynamically stable, the first decision is whether to pursue rate control or rhythm control. Landmark trials (AFFIRM, RACE) demonstrated that rate control is non-inferior to rhythm control for most patients in terms of mortality, making rate control the default strategy for many patients, particularly the elderly and those with minimal symptoms. However, rhythm control is preferred for younger, symptomatic patients and those with new-onset atrial fibrillation, heart failure, or a desire to maintain sinus rhythm.

Rate Control

The goal of rate control is to keep the resting ventricular rate below 110 bpm (lenient control, based on the RACE II trial) or below 80 bpm if the patient remains symptomatic despite lenient control.

For patients with HFrEF, beta-blockers (metoprolol succinate, carvedilol, bisoprolol) remain first-line. Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) are absolutely contraindicated because their negative inotropic effect worsens heart failure. Digoxin can be added as adjunct therapy.

Rhythm Control

If the arrhythmia has been present for less than 48 hours, cardioversion (electrical or pharmacological) can proceed without prior anticoagulation or TEE. If the duration is greater than 48 hours or unknown, either obtain a TEE to exclude left atrial appendage thrombus, or anticoagulate with a therapeutic agent for 3 to 4 weeks before attempting cardioversion. After successful cardioversion, anticoagulation must be continued for at least 4 weeks, and long-term anticoagulation decisions then follow the ${\text{CHA}}_2{\text{DS}}_2\text{-VASc}\backslash text\{CHA\}\_2\backslash text\{DS\}\_2\backslash text\{-VASc\}$ score.

Antiarrhythmic Drug Selection

A critical rule: Flecainide and propafenone (Class IC agents) are contraindicated in patients with structural heart disease, including coronary artery disease, heart failure, and significant left ventricular hypertrophy. This is based on the CAST trial, which showed increased mortality with Class IC agents in post-MI patients. Expect this as a distractor.

Dronedarone is another Class III agent that can be used for maintenance of sinus rhythm but is contraindicated in NYHA Class III or IV heart failure and in permanent atrial fibrillation (the PALLAS trial demonstrated increased mortality).

Catheter ablation (pulmonary vein isolation) is indicated when antiarrhythmic drugs fail or are not tolerated. It is most effective in paroxysmal atrial fibrillation and in patients with fewer comorbidities. Recent evidence (CASTLE-AF, CABANA) supports early ablation in selected heart failure patients.

Anticoagulation for Stroke Prevention

The ${\text{CHA}}_2{\text{DS}}_2\text{-VASc}\backslash text\{CHA\}\_2\backslash text\{DS\}\_2\backslash text\{-VASc\}$ score determines the need for long-term anticoagulation:

Anticoagulation recommendations:

• Score of 0 in males or 1 in females (where the only point is sex category): No anticoagulation needed.

• Score of 1 in males: Consider anticoagulation (clinical judgment).

• Score of 2 or greater: Anticoagulation is recommended.

DOACs are preferred over warfarin for non-valvular atrial fibrillation because they have predictable pharmacokinetics, require no routine INR monitoring, and have fewer drug and food interactions. Warfarin remains mandatory for valvular atrial fibrillation.

For patients who cannot tolerate any anticoagulation, left atrial appendage occlusion (e.g., Watchman device) is a procedural alternative for stroke prevention.

Atrial Fibrillation with Wolff-Parkinson-White (WPW)

This is one of the most tested and most dangerous scenarios. In WPW, an accessory pathway (Bundle of Kent) bypasses the AV node. If atrial fibrillation develops, impulses can conduct rapidly through this accessory pathway directly to the ventricles, potentially causing ventricular fibrillation and sudden death.

AV nodal blockers (beta-blockers, calcium channel blockers, digoxin, and adenosine) are absolutely contraindicated because blocking the AV node removes the only "brake" on conduction and forces all impulses through the accessory pathway.

The correct treatment is IV procainamide (which slows conduction through the accessory pathway) or electrical cardioversion if the patient is unstable.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on atrial fibrillation questions is by mishandling the cardioversion timeline. When a stable patient presents with atrial fibrillation of unknown or prolonged duration (greater than 48 hours), jumping directly to cardioversion without first addressing the thrombus risk is a classic error. The correct sequence is either TEE to exclude clot or 3 to 4 weeks of anticoagulation before cardioversion. Conversely, an unstable patient always gets immediate cardioversion regardless of clot risk, and choosing "start heparin first" or "get a TEE" in that scenario is the trap answer.

The second major pitfall involves WPW with atrial fibrillation. When the vignette describes a young patient with a wide-complex, irregularly irregular tachycardia and a history of pre-excitation or delta waves, students often reflexively choose a beta-blocker or calcium channel blocker for rate control. This is the single most dangerous wrong answer on the exam, as AV nodal blockade can precipitate ventricular fibrillation. The correct answer is procainamide or cardioversion.

Students also confuse atrial flutter with atrial fibrillation. Both are atrial arrhythmias, both carry thromboembolic risk, and both may require cardioversion. But the ECG is the discriminator: a regular rhythm at about 150 bpm with sawtooth waves is flutter, not fibrillation. The management overlaps (anticoagulation, rate vs. rhythm control), but flutter is more amenable to catheter ablation of the cavotricuspid isthmus.

Another frequently tested trap is choosing a Class IC antiarrhythmic (flecainide, propafenone) in a patient with structural heart disease. Vignettes will describe a patient with coronary artery disease or reduced ejection fraction and ask for the best antiarrhythmic. Flecainide increases mortality in this population. The answer in HFrEF is amiodarone or dofetilide.

Finally, remember the valvular vs. non-valvular distinction. If the vignette describes mitral stenosis (particularly rheumatic) or a mechanical heart valve, the anticoagulant must be warfarin. DOACs are ineffective and harmful in this population. Any question that describes a new DOAC in a patient with a mechanical valve is testing whether you will recognize this contraindication.

The core competency being tested across all atrial fibrillation questions is the ability to integrate rhythm identification, hemodynamic assessment, stroke risk stratification, and drug selection into a coherent management plan. The exam rewards students who can sequence decisions correctly: stabilize first, then decide rate versus rhythm, then address anticoagulation, with every drug choice filtered through the patient's structural heart disease status and comorbidities.